OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Olawaiye on Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 25th 2025

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

Dr Stein on the Emerging Role of Menin Inhibitors in Frontline Combinations for AML

June 25th 2025

Eytan M. Stein, MD, discusses the emerging role of menin inhibitors such as revumenib in combination treatment strategies for AML.

Dr Kuykendall on the Rationale for Targeting the Hepcidin Pathway With Rusfertide in Polycythemia Vera

June 24th 2025

Andrew Kuykendall, MD, discusses the rationale for using rusfertide to target the hepcidin pathway in patients with polycythemia vera.

Dr Vose on the Durability of Response to Epcoritamab Monotherapy in DLBCL

June 24th 2025

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Dr McArthur on the Expanding Clinical Impact of ADCs in HER2+ Breast Cancer

June 24th 2025

Heather McArthur, MD, MPH, discusses the expanding clinical impact of ADCs in HER2-positive breast cancer.

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

June 24th 2025

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Dr Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC

June 23rd 2025

Balazs Halmos, MD, MS, discusses the FDA’s accelerated approval of datopotamab deruxtecan for EGFR-mutated NSCLC.

Dr Mascarenhas on the Efficacy of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 23rd 2025

John O. Mascarenhas, MD, discussed findings from the IMproveMF trial investigating imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Dr Fankuchen on Practice-Informing Updates to the Thoracic Oncology Treatment Paradigm

June 23rd 2025

Olivia Fankuchen, MD, MS, highlights molecular targets, trial data, and real-world experiences that have immediate implications for the lung cancer field.

Dr Amanam on the Real-World Efficacy of First-Line Luspatercept vs Erythropoiesis-Stimulating Agents in Lower-Risk MDS

June 23rd 2025

Idoroenyi Amanam, MD, discusses the efficacy of first-line luspatercept vs erythropoiesis-stimulating agents in real-world patients with lower-risk MDS.

Dr Pal on Genomic Activity With Adjuvant Atezolizumab vs Placebo in High-Risk Resected RCC

June 23rd 2025

Sumanta Kumar Pal, MD, FASCO, discusses the genomic activity of adjuvant atezolizumab vs placebo in patients with high-risk resected RCC.

Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

June 23rd 2025

Premal H. Thaker, MD, discusses safety and efficacy data for IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed ovarian cancer.

Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC

June 23rd 2025

Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.

Paulus on the Rationale for Utilizing an External Control Arm in a Single-Arm HER2+ Breast Cancer Trial

June 23rd 2025

Jessica Paulus, ScD, explains the rationale for utilizing an external control arm in a single-arm phase 2 HER2-positive metastatic breast cancer trial.

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

June 23rd 2025

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

June 23rd 2025

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

Dr Saghir on Ribociclib Plus Endocrine Therapy in Premenopausal HR+/HER2-Negative Advanced Breast Cancer

June 23rd 2025

Nagi S. El-Saghir, MD, FACP, FASCO, discusses ribociclib plus endocrine therapy in premenopausal HR-positive breast cancer by liver metastases status.

Dr Danilov on the Manuscript From Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma

June 20th 2025

Alexey Danilov, MD, PhD, discusses the significance of a manuscript that was published following the first Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Dr Abramson on Findings with Glofitamab, Gemcitabine and Oxaliplatin in R/R DLBCL

June 20th 2025

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.